Health news new prostate cancer treatment added to pbs 20230524 p5ys4m.html – Breaking News & Latest Updates 2026
Advertisement
Advertisement
This was published 3 years ago

Prostate cancer treatment worth $40,000 a year to be listed on PBS

Lucy Slade

Powered by

A significant prostate cancer treatment is about to become more affordable for men across the country.

Men living with metastatic hormone sensitive prostate cancer will be able access Erlyand (apalutamide) on the Pharmaceutical Benefits Scheme (PBS) from June, which currently costs patients about $40,000 a year.

The specific cancer effects about 3000 Australian men and apalutamide has proven to boost survival rates.

Advertisement

READ MORE: Young girl forced to leap from freefall ride

Men living with metastatic hormone sensitive prostate cancer will be able access Erlyand (apalutamide) on the Pharmaceutical Benefits Scheme (PBS) from June, which currently costs patients about $40,000 a year.

Men living with metastatic hormone sensitive prostate cancer will be able access Erlyand (apalutamide) on the Pharmaceutical Benefits Scheme (PBS) from June Nine

Currently two in three men with stage four prostate cancer in Australia do not survive.

Graham Oldfield said a swollen lymph node was the only warning sign of his cancer.

"He did a biopsy and found one half of the prostate was destroyed by cancer and it also spread through my body... through my lymphatic system, it is in my spine, it is in my lung," Oldfield.

READ MORE: News of Rolf Harris' death withheld for weeks

Men living with metastatic hormone sensitive prostate cancer will be able access Erlyand (apalutamide) on the Pharmaceutical Benefits Scheme (PBS) from June, which currently costs patients about $40,000 a year. Graham Oldfield

Graham Oldfield said his treatment costs about $40,000 per year. Nine

Oldfield said Apalutamide worked better and had less side effects than the other drugs.

Advertisement

The PBS will reduce the cost of the drugs to $30 per script, or about $7.30 for pension card holders.

Professor Anthony Joshua at St Vincent's Hospital said prostate cancer uses testosterone to fuel its growth, which was why men were given hormone injections.

"Then the cancer realises there is no testosterone around anymore and it starts to make its own testosterone and that's what these drugs are very good at blocking," Joshua said.

READ MORE: Four charged with murder of Cassius Turvey plead not guilty

Advertisement
Advertisement
Men living with metastatic hormone sensitive prostate cancer will be able access Erlyand (apalutamide) on the Pharmaceutical Benefits Scheme (PBS) from June, which currently costs patients about $40,000 a year.

Professor Anthony Joshua at St Vincent's Hospital said prostate cancer used testosterone to fuel its growth. Nine

"These class of drugs are very effective in helping men live longer and live better."

Federal health minister Mark Butler said the PBS listing would make a dramatic change for men and prostate cancer suffers.

"It is a treatment that can be taken at home without attending a hospital or other medical facility," Butler said.

Advertisement

This is the first drug of its kind to be listed on the PBS for men whose cancer has spread.

Last year it was subsidised for those with earlier stage disease.

Prostate cancer is the most diagnosed cancer in Australia and the second most deadly.

Sign up here to receive our daily newsletters and breaking news alerts, sent straight to your inbox.

email icon

Contact us

Share a tip-off, video or photo with us

Most viewed in Australia

More to explore